Formosa LaboratoriesTPE:4746 -2.31%70 EBITDA Margin % is 21.66% as of Dec. 2025, which is 2% below its 10-year median of 22.11. GuruFocus rates TPE:4746 with a GF Score™ of 70/100 and a GF Value™ of NT$98.73 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Formosa Laboratories ranks better than 73.82% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Formosa Laboratories EBITDA Margin % Related Terms
Formosa Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Formosa Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Formosa Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formosa Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Formosa Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Formosa Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formosa Laboratories (TPE:4746) has a EBITDA Margin % of 21.66% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Formosa Laboratories and its competitors. This is near median its historical median of 22.11. Over the past decade, Formosa Laboratories' EBITDA Margin % has ranged from 13.51 to 50.62. According to the industry distribution chart, Formosa Laboratories ranks #250 out of 955 companies in the Drug Manufacturers industry, placing it in the top 26.2%.
Is Formosa Laboratories' EBITDA Margin % too high?
Formosa Laboratories' current EBITDA Margin % of 21.66% is near median its 10-year median of 22.11. Over the past 10 years, this metric has ranged from a low of 13.51 to a high of 50.62. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Formosa Laboratories' value of 21.66% is 74.1% above this industry median. Based on the distribution chart, Formosa Laboratories ranks #250 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Formosa Laboratories has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formosa Laboratories' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Formosa Laboratories ranks #250 out of 955 companies for EBITDA Margin %. This puts Formosa Laboratories in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Formosa Laboratories' value of 21.66% is 74.1% above this benchmark. Historically, Formosa Laboratories' own EBITDA Margin % has ranged from 13.51 to 50.62 over the past decade. While the company's 10-year median is 22.11 vs. the industry median of 12.44, Formosa Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formosa Laboratories's current EBITDA Margin % of 21.66% is 74.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Formosa Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formosa Laboratories's current EBITDA Margin % is 21.66%, which is near median its own 10-year median of 22.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Formosa Laboratories (TPE:4746) is currently considered Possible Value Trap. The stock's GF Value™ is NT$98.73, compared to a current price of NT$50.80 — trading 48.5% below its estimated fair value. The current EBITDA Margin % is 21.66%, which is near median its 10-year median of 22.11 and 74.1% above the Drug Manufacturers industry median of 12.44. Formosa Laboratories' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Formosa Laboratories (TPE:4746), the current EBITDA Margin % is 21.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formosa Laboratories (TPE:4746) Overvalued in 2026?
Based on GuruFocus' analysis, Formosa Laboratories stock appears to be undervalued.
The current stock price of NT$50.80 is trading 48.5% below its estimated GF Value™ of NT$98.73.
GuruFocus considers Formosa Laboratories to be Possible Value Trap.
Key valuation signals for TPE:4746:
EBITDA Margin %: 21.66% (near median its 10-year median of 22.11)
GF Value™: NT$98.73 vs. price of NT$50.80 (48.5% below fair value)
Industry Position: 74.1% above the Drug Manufacturers median (#250 of 955)
No single metric tells the full story. See the TPE:4746 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formosa Laboratories Inc is mainly engaged in the wholesale and manufacturing of active pharmaceutical ingredients, as well as ultraviolet absorbers. The company geographically operates in India, Taiwan, Netherlands, Switzerland, Germany, Japan, China, Canada, United States, and Others.
70GF Score
Get the complete analysis for TPE:4746
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4746 has been successfully added to your 
